1.03  0.046 (4.65%)		07-30 16:00
Open: 0.9705 High: 1.05 Volume: 82,975		Pre. Close: 0.9842 Low: 0.9506 Market Cap: 12(M)

Short term
Mid term
Targets	6-month :	1.33	1-year :	1.55
Resists	First :	1.13	Second :	1.33
Pivot price	1.02
Supports	First :	0.95	Second :	0.83
MAs	MA(5) :	1.02	MA(20) :	1.02
	MA(100) :	1.13	MA(250) :	1.42
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	56	D(3) :	59.5
RSI	RSI(14): 49.3
52-week	High :	4.19	Low :	0.81

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PHIO ] has closed below upper band by 49.2%. Bollinger Bands are 23.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.05 - 1.06	1.06 - 1.06
Low:	0.94 - 0.94	0.94 - 0.95
Close:	1.02 - 1.03	1.03 - 1.04

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

Thu, 30 Jul 2026
Phio Pharmaceuticals Corp (PHIO) Valuation: PE, PB & Fair Value Analysis - tradingkey.com

Tue, 28 Jul 2026
PHIO|Phio Pharmaceuticals Corp|Price:1.010|Chg%:-0.040 - tradingkey.com

Fri, 24 Jul 2026
Phio Pharmaceuticals Market Sentiment - Benzinga España

Fri, 24 Jul 2026
Phio Pharmaceuticals Corp. Revenue Breakdown – NASDAQ:PHIO - TradingView

Wed, 22 Jul 2026
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile

Tue, 21 Jul 2026
Phio Pharmaceuticals appoints dermatologist to board - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	12 (M)
Shares Float	12 (M)
Held by Insiders	1.9 (%)
Held by Institutions	10.8 (%)
Shares Short	178 (K)
Shares Short P.Month	302 (K)

EPS	-1.38
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.41
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-46.7 %
Return on Equity (ttm)	-76.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.57
Sales Per Share	0
EBITDA (p.s.)	-1
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-0.75
PEG Ratio	0
Price to Book value	0.72
Price to Sales	0
Price to Cash Flow	-1.12

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.